| Assessment Status | Rapid Review Complete |
| HTA ID | 25063 |
| Drug | Lonafarnib |
| Brand | Zokinvy® |
| Indication | Lonafarnib is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation. |
| Assessment Process | |
| Rapid review commissioned | 28/10/2025 |
| Rapid review completed | 27/11/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends lonafarnib not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.